{"id":"camrelizumab-famitinib-malate","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-15%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Anorexia"},{"rate":"5-10%","effect":"Weight loss"}]},"_chembl":{"chemblId":"CHEMBL4297715","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PD-1/PD-L1 interaction, camrelizumab allows T-cells to recognize and attack cancer cells more effectively. This mechanism is thought to be responsible for its anti-tumor activity. Camrelizumab has been shown to be effective in treating various types of cancer, including non-small cell lung cancer and multiple myeloma.","oneSentence":"Camrelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:43.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07143292","phase":"PHASE2","title":"A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-11-30","conditions":"Cervical Cancer Metastatic, Cervical Cancer Recurrent","enrollment":120},{"nctId":"NCT04906993","phase":"PHASE3","title":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-23","conditions":"Cervical Cancer","enrollment":443},{"nctId":"NCT05208177","phase":"PHASE2","title":"A Study of SHR-1802 in Patients With Advanced Solid Tumor","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-04-22","conditions":"Advanced Solid Tumor","enrollment":25},{"nctId":"NCT05106335","phase":"PHASE3","title":"A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-01-06","conditions":"Advanced NSCLC","enrollment":1},{"nctId":"NCT05214976","phase":"PHASE2","title":"A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-08-12","conditions":"Advanced Solid Tumors","enrollment":64},{"nctId":"NCT05042375","phase":"PHASE3","title":"A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-09-08","conditions":"Non-small Cell Lung Cancer","enrollment":450},{"nctId":"NCT03827837","phase":"PHASE2","title":"Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-01-23","conditions":"Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer","enrollment":265},{"nctId":"NCT05005468","phase":"PHASE2","title":"A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2021-09","conditions":"NSCLC","enrollment":61},{"nctId":"NCT04044378","phase":"PHASE1, PHASE2","title":"Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma","status":"WITHDRAWN","sponsor":"Peking University People's Hospital","startDate":"2019-08-15","conditions":"Effect of Drugs, Progression, Pediatric Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"camrelizumab； famitinib malate","genericName":"camrelizumab； famitinib malate","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immune response. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}